Completed PHASE3 INTERVENTIONAL 2-arm NCT00128102

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy

Sponsor: Merck Sharp & Dohme LLC

Conditions Lung Cancer Mesothelioma

Interventions Placebo Vorinostat

Updated 8 times since 2017 Last updated: Oct 1, 2020 Started: Jun 30, 2005 Primary completion: Jul 15, 2011 Completion: Nov 21, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00128102, this PHASE3 trial focuses on Lung Cancer and Mesothelioma and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3
Nov 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.